|
|
|
|
|
07.05.26 - 11:12
|
Halozyme and Oruka sign agreement for Hypercon technology (PBR)
|
|
|
Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one
The post Halozyme and Oruka sign agreement for Hypercon technology appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
30.04.26 - 14:03
|
Halozyme Appoints Darren Snellgrove as Chief Financial Officer (PR Newswire)
|
|
|
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. Mr. Snellgrove will be responsible for leading Halozyme's financial......
|
|
|
30.04.26 - 14:03
|
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations (Business Wire)
|
|
|
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph J. Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme.
“Ryan's appointment underscores the deep bench of financial talent within Johnson & Johnson and our commitment to developing leaders across the Company,” said Mr. Wolk. “With his deep knowledge of our business and proven financial expertise, Ryan is exceptionally well positioned to lead our Investor Relations function and will be a great resource to the investment community as we continue to execute our long-term strategy, drive sustained and accelerating growth and create value for shareholders.”
Mr. Koors is an accomplished Johnson & Johnson finance leader with more than 20 years of...
|
|
|
|
|
08.04.26 - 11:48
|
Halozyme and Vertex sign deal for Hypercon technology (PBR)
|
|
|
Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics,
The post Halozyme and Vertex sign deal for Hypercon technology appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.03.26 - 12:03
|
Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science (Business Wire)
|
|
|
Fund III is actively being deployed, with three new seed investments in founder-led companies unlocking the complexity of science with AI.
Fund II portfolio company Surf Bio recently announced its acquisition by Halozyme (HALO) for up to $400M.SAN FRANCISCO--(BUSINESS WIRE)--Breakout Ventures today announced the close of its $114M Fund III. Since its launch in 2016, Breakout Ventures has partnered with exceptional founders to scale scientific innovation and build breakout companies. Given Breakout's ongoing success, the new fund received strong support from returning investors including Cortes Capital, S-Cubed Capital, The Kraft Group, Pinegrove Venture Partners, and an affiliate of LH Capital, and is pleased to add new limited partners including JIMCO, the global investment arm of the Jameel family, and Korea Omega Investment Corporation.
With the launch of this new fund, Managing Partner Lindy Fishburne said, “We've spent the last decade investing early in founding teams using technology to harness ...
|
|
|
|
|
|
|
25.02.26 - 14:33
|
Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
|
|
|
SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present and host investor meetings at the following investor conferences: Event: TD Cowen 46th......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
